HC Wainwright set a $3.00 price target on Cancer Genetics (NASDAQ:CGIX) in a research report report published on Wednesday, September 19th. The brokerage currently has a buy rating on the medical research company’s stock.
A number of other equities analysts also recently commented on the company. Maxim Group reissued a hold rating on shares of Cancer Genetics in a research report on Tuesday, August 14th. Zacks Investment Research raised Cancer Genetics from a sell rating to a hold rating in a research report on Tuesday, July 3rd. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Cancer Genetics presently has a consensus rating of Hold and an average price target of $4.50.
NASDAQ CGIX traded down $0.01 during trading on Wednesday, hitting $0.84. The stock had a trading volume of 93,487 shares, compared to its average volume of 334,319. The company has a market cap of $28.86 million, a P/E ratio of -1.06 and a beta of 0.52. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.66 and a quick ratio of 0.66. Cancer Genetics has a twelve month low of $0.82 and a twelve month high of $3.50.
An institutional investor recently raised its position in Cancer Genetics stock. Renaissance Technologies LLC lifted its stake in shares of Cancer Genetics Inc (NASDAQ:CGIX) by 22.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 587,300 shares of the medical research company’s stock after buying an additional 105,900 shares during the quarter. Renaissance Technologies LLC owned approximately 2.12% of Cancer Genetics worth $523,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 14.83% of the company’s stock.
Cancer Genetics Company Profile
Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Featured Article: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.